Program
dupilumab
Also written as “Dupilumab”, “Dupilumab SAR231893” and “Dupilumab (SAR231893)”.
Its studies are mostly in Dermatitis, Atopic · Asthma · Eosinophilic Esophagitis · Nasal Polyps · Pulmonary Disease, Chronic Obstructive, led by 3 companies.
Drug pageDupilumab: every studyAll 180 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 529 open or running | phase 4since Jul 16, 2019 | Mar 9, 2011 | Feb 7, 2027phase 4 · NCT07905547 |
| Regeneron Pharmaceuticals | 404 open or running | phase 4since Dec 17, 2019 | Nov 10, 2009 | Apr 24, 2027phase 4 · NCT06572228 |
| Andover Eye Associatesits history only | 11 open or running | phase 2since Mar 2, 2020 | Mar 2, 2020 | none ahead |
Also a collaborator on its studies: Aimmune Therapeutics and Statistics & Data.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Regeneron Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 26 studies since Nov 10, 2009.
- Sep 21, 2018Phase 2 study in Peanut HypersensitivityNCT03682770 · 148 enrolled · United States
- Nov 7, 2018Phase 2 study in Dermatitis, AtopicNCT03736967 · 206 enrolled · United States, Belgium, Czechia and more
- Jan 2, 2019Phase 2 study in Peanut HypersensitivityNCT03793608 · 25 enrolled · United States, Canada
- Dec 17, 2019Phase 4 study in AsthmaNCT04203797 · 40 enrolled · United States, France, Germany and more
- Dec 18, 2019Phase 3 study in Pemphigoid, BullousNCT04206553 · 106 enrolled · United States, Australia, France and more
- May 7, 2020Phase 3 study in Eosinophilic EsophagitisNCT04394351 · 102 enrolled · United States, Canada
- Jun 2, 2020Phase 3 study in Moderate to Severe Atopic Hand and Foot DermatitisNCT04417894 · 133 enrolled · United States, Germany, Japan and more
- Jun 4, 2020Phase 2 study in Aspergillosis, Allergic BronchopulmonaryNCT04442269 · 62 enrolled · United States, Bulgaria, France and more
- Oct 18, 2022Phase 4 study in Dermatitis, AtopicNCT05590585 · 124 enrolled · United States
- Apr 14, 2023Phase 2 study in Eosinophilic enteropathyNCT05831176 · 22 enrolled · United States, Canada, Italy and more
- Aug 23, 2024Phase 4 study in AsthmaNCT06572228 · 120 enrolled · United States, Canada, Denmark and more
- Aug 1, 2025Phase 3 study in Eosinophilic EsophagitisNCT07112378 · 20 planned · United States
- Sep 15, 2025Phase 4 study in Dermatitis, AtopicNCT07187089
- May 8, 2026Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT07587658 · 754 planned · United States
Ahead
- Apr 24, 2027Primary completion: phase 4 study in AsthmaNCT06572228
- Jun 19, 2028Primary completion: phase 3 study in Eosinophilic EsophagitisNCT07112378
- Jul 30, 2028Primary completion: phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT07587658
TargetBeta
“Interleukin-4 receptor subunit alpha antagonist”ChEMBL 37, by rule
Other programs on IL4R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| drotokibart | Jiangsu HengRui Medicine | phase 3 | 8 |
| TQH2722 | Sino Biopharmaceutical | phase 3 | 7 |
| SHR-1819 | Jiangsu HengRui Medicine | phase 3 | 5 |
Studies
All 40 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07587658Pulmonary Disease, Chronic Obstructive · United States | 4 | Recruiting | Jul 30, 2028 | 754 |
| NCT07187089Dermatitis, Atopic | 4 | Withdrawn | Dec 23, 2027 | 0 |
| NCT07112378Eosinophilic Esophagitis · United States | 3 | Recruiting | Jun 19, 2028 | 20 |
| NCT06572228Asthma · United States, Canada, Denmark and more | 4 | Active, not recruiting | Apr 24, 2027 | 120 |
| NCT05831176Eosinophilic enteropathy · United States, Canada, Italy and more | 2 | Active, not recruiting | Feb 23, 2026 | 22 |
| NCT05590585Dermatitis, Atopic · United States | 4 | Completed | Nov 14, 2024 | 124 |
| NCT04442269Aspergillosis, Allergic Bronchopulmonary · United States, Bulgaria, France and more | 2 | Completed | Jul 27, 2023 | 62 |
| NCT04417894Moderate to Severe Atopic Hand and Foot Dermatitis · United States, Germany, Japan and more | 3 | Completed | Aug 31, 2022 | 133 |
| NCT04394351Eosinophilic Esophagitis · United States, Canada | 3 | Completed | Jun 2, 2022 | 102 |
| NCT04206553Pemphigoid, Bullous · United States, Australia, France and more | 3 | Completed | Jul 12, 2024 | 106 |
| NCT04203797Asthma · United States, France, Germany and more | 4 | Completed | Jul 15, 2023 | 40 |
| NCT03793608Peanut Hypersensitivity · United States, Canada | 2 | Completed | Feb 19, 2021 | 25 |
| NCT03736967Dermatitis, Atopic · United States, Belgium, Czechia and more | 2 | Terminated | Mar 13, 2020 | 206 |
| NCT03682770Peanut Hypersensitivity · United States | 2 | Completed | Oct 16, 2020 | 148 |
| NCT03633617Eosinophilic Esophagitis · United States, Australia, Belgium and more | 3 | Completed | Sep 9, 2021 | 321 |
| NCT03558997Rhinitis, Allergic · United States, Canada | 2 | Completed | May 14, 2019 | 103 |
| NCT03345914Dermatitis, Atopic · United States, Canada, Czechia and more | 3 | Completed | Jun 20, 2019 | 367 |
| NCT03112577Asthma · United States, United Kingdom | 1 | Completed | Mar 20, 2019 | 32 |
| NCT03054428Dermatitis, Atopic · United States, Canada | 3 | Completed | Apr 4, 2018 | 251 |
| NCT03050151Dermatitis, Atopic · United States | 1 | Completed | Nov 14, 2017 | 176 |
| NCT03346434Dermatitis, Atopic · United States, Germany, Poland and more | 3 | Completed | Jul 8, 2021 | 202 |
| NCT02755649Dermatitis, Atopic · Austria, Belgium, Germany and more | 3 | Completed | Jan 4, 2017 | 325 |
| NCT02647086Dermatitis, Atopic · United States | 1 | Completed | Jul 2016 | 14 |
| NCT02612454Dermatitis, Atopic · United States, Canada, Czechia and more | 3 | Completed | Oct 9, 2026 | 880 |
| NCT02407756Dermatitis, Atopic · Canada, Czechia, Germany and more | 2 | Completed | Mar 31, 2016 | 78 |
| NCT02395133Dermatitis, Atopic | 3 | Completed | Jul 2016 | 422 |
| NCT02379052Eosinophilic Esophagitis · United States | 2 | Completed | Feb 17, 2017 | 47 |
| NCT02277769Dermatitis, Atopic · United States, Canada, France and more | 3 | Completed | Oct 31, 2015 | 708 |
| NCT02277743Dermatitis, Atopic · United States, Bulgaria, Canada and more | 3 | Completed | Nov 2015 | 671 |
| NCT02260986Dermatitis, Atopic · United States, Australia, Canada and more | 3 | Completed | Aug 2015 | 740 |
| NCT02210780Dermatitis, Atopic · United States | 2 | Completed | Sep 15, 2015 | 194 |
| NCT01979016Dermatitis, Atopic · United States, Canada | 2 | Completed | Dec 31, 2014 | 54 |
| NCT01949311Dermatitis, Atopic · United States, Australia, Austria and more | 3 | Completed | Jun 27, 2022 | 2,733 |
| NCT01859988Dermatitis, Atopic · United States, Canada, Czechia and more | 2 | Completed | May 2014 | 380 |
| NCT01639040Dermatitis, Atopic · Germany, Hungary, Poland | 2 | Completed | Dec 2012 | 31 |
| NCT01548404Dermatitis, Atopic · Czechia, France, Germany and more | 2 | Completed | Mar 2013 | 109 |
| NCT01484600Healthy · United States | 1 | Completed | Feb 2012 | 36 |
| NCT01385657Dermatitis, Atopic · Australia, Germany, New Zealand | 1 | Completed | Mar 31, 2012 | 37 |
| NCT01259323Dermatitis · United States | 1 | Completed | Jul 2012 | 30 |
| NCT01015027Healthy · United States | 1 | Completed | Jul 2010 | 48 |
How it is read
Names in the registry
- “Dupilumab”, 55 entries
- “Dupilumab SAR231893”, 13 entries
- “dupilumab”, 10 entries
- “Dupilumab (SAR231893)”, 5 entries
- “REGN668”, 4 entries
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 32 studies
- Asthma, 17 studies
- Eosinophilic Esophagitis, 5 studies
- Nasal Polyps, 5 studies
- Pulmonary Disease, Chronic Obstructive, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.